Researchers are testing a radiation technique that compresses an entire cancer treatment dose into a fraction of a second, aiming to kill tumors while leaving healthy tissue largely unharmed. FLASH radiotherapy delivers 10 or more gray of radiation at dose rates exceeding 40 Gy per second, finishing in under 500 milliseconds. Early human cases and a growing body of preclinical data suggest this speed differential produces a biological advantage that conventional radiation cannot match, though the field is still working to prove the effect holds across tumor types and patient populations.
What Defines FLASH and Why Speed Matters
Standard radiation therapy sessions spread dose delivery over minutes. FLASH compresses that same energy into pulses lasting microseconds to milliseconds. The operational threshold, established in foundational mouse studies published in Science Translational Medicine, requires an ultrahigh dose rate of at least 40 Gy/s delivered in 500 ms or less. Those experiments showed reduced lung fibrosis in mice below certain single-dose thresholds while maintaining equivalent tumor growth control compared to conventional-rate irradiation.
The speed itself appears to be the active ingredient. At conventional dose rates, radiation generates reactive oxygen species that damage both cancerous and normal cells indiscriminately over the course of the exposure. One leading hypothesis holds that FLASH delivery depletes local oxygen so rapidly that normal tissue enters a transient protective state. Research in mouse brain models, reported in PNAS, found that oxygen dynamics during ultra-fast delivery promote radical recombination and preserve neurocognitive function in irradiated animals over the long term, an outcome not seen at standard dose rates. Tumors, which are already hypoxic and metabolically disordered, do not appear to gain the same protection.
Alternative mechanistic ideas are also under investigation. Some groups are examining whether FLASH preferentially spares certain stem cell niches or alters DNA damage signaling kinetics in normal tissue. Others are probing whether immune modulation plays a role, given that immune cells are highly radiosensitive and circulate through the treatment field during exposure. At this stage, no single explanation has been universally accepted, and the protective “FLASH effect” may ultimately prove to be multifactorial.
From Mice to Patients: Early Clinical Evidence
The first reported human FLASH treatment involved a 75-year-old patient with a 3.5‑cm cutaneous lymphoma lesion. Clinicians used a dedicated 5.6‑MeV linear accelerator to deliver a single fraction of 15 Gy in 90 milliseconds, achieving an average dose rate of roughly 167 Gy/s. The patient experienced only grade 1 epithelitis and edema as acute side effects, and a rapid complete response followed. That case, while limited to a single superficial tumor, demonstrated that the dose rates required for FLASH could be achieved and tolerated in a clinical setting.
A second milestone came when a 68‑year‑old female patient with melanoma of the right foot received electron-based FLASH treatment upon disease progression to the lower leg. That case used a modified clinical linac rather than a purpose-built research machine, signaling that existing hospital equipment could potentially be adapted for FLASH delivery. The treatment achieved local control with acceptable toxicity, though the follow-up period was relatively short and the experience remains anecdotal.
Neither case, however, involved the deep-seated solid tumors that account for most cancer deaths. Skin lesions are accessible with electrons that penetrate only a few centimeters. Reaching lung, liver, or brain tumors at FLASH dose rates demands either high-energy protons or heavily modified photon beams, and that engineering challenge remains partially unsolved. As a result, clinicians are proceeding cautiously, prioritizing safety and feasibility studies before moving into large efficacy trials.
Proton FLASH Enters Clinical Testing
The FAST‑01 trial, listed on ClinicalTrials.gov as NCT04592887, represents the first prospective FLASH feasibility study in humans. It enrolled patients with painful extremity bone metastases and used proton beam delivery rather than electrons. The trial’s endpoints focus on workflow feasibility, acute toxicity, and pain relief rather than tumor shrinkage, reflecting how early the field remains in its clinical translation. By selecting palliative indications, investigators can evaluate safety while still offering potential symptom benefit.
Proton pencil beam scanning (PBS) systems present a distinct technical puzzle. Unlike broad electron beams that can blanket a target in a single pulse, PBS paints the tumor voxel by voxel. Achieving FLASH-relevant dose rates across the entire treatment volume requires careful planning. Modeling work in Acta Oncologica examined whether clinically planned PBS treatments could sustain rates above 40 Gy/s throughout the target and found that machine constraints, including magnet scanning speed and beam current limits, impose real boundaries on which tumor geometries qualify for FLASH.
A related concern is how to even define “dose rate” for a scanning beam. A single spot may deliver radiation at instantaneous rates exceeding one million Gy/s, but the average rate across the full volume can be far lower. Standardization frameworks have proposed volumetric criteria that specify what fraction of the target must receive a given minimum dose rate, in order to prevent misleading claims about whether a treatment truly met FLASH conditions. These definitions will be critical as more centers report early clinical experiences and attempt cross-institutional comparisons.
Preclinical Evidence Beyond Skin Deep
Much of the confidence in FLASH rests on animal data gathered across species and organ systems. Studies in mini-pigs and cats with spontaneous cancers provided translational evidence that FLASH spares normal tissue at scales larger than a laboratory mouse. The cat patients, treated for naturally occurring tumors rather than artificially implanted ones, offered a closer analog to human oncology than most preclinical models and showed encouraging toxicity profiles alongside effective tumor dosing.
Brain irradiation experiments have been especially striking. When mice received 10 Gy in 1 to 10 pulses of approximately 1.8 microseconds each, reaching instantaneous dose rates above one million Gy/s, researchers observed reduced reactive gliosis compared to conventional exposures. Gliosis is a hallmark of radiation-induced brain injury, and its reduction at FLASH rates suggests the technique could eventually benefit patients undergoing whole-brain or partial-brain radiation, where cognitive decline is a major quality-of-life concern.
Preclinical work has also examined thoracic, abdominal, and pelvic targets. In lung models, FLASH has reduced fibrosis and preserved respiratory function at doses that would normally cause severe scarring, while still controlling implanted tumors. Gastrointestinal studies hint that ultra-fast delivery may better spare the delicate mucosa of the small intestine and rectum, which often limit dose escalation in conventional radiotherapy. These organ-specific findings, though still early, support the idea that the FLASH effect is not confined to a single tissue type.
Open Questions and the Road Ahead
Despite the excitement, key questions remain before FLASH can be widely adopted. Investigators still need to determine which combinations of total dose, dose rate, fractionation, and beam modality reliably produce a protective effect in humans. It is not yet clear whether every normal tissue benefits equally, or whether certain organs (such as the brain and lung) are particularly amenable while others may show little difference from conventional treatment.
Technical barriers are equally significant. Only a limited number of centers currently have machines capable of delivering clinically useful FLASH beams, and most of those are operating in research modes with strict protocols. Treatment planning systems must incorporate dose-rate constraints alongside traditional metrics like dose–volume histograms, and quality assurance procedures must verify that ultrahigh dose rates are achieved safely and reproducibly.
Regulators and professional societies are beginning to discuss how best to categorize FLASH within existing radiation therapy frameworks. For now, most human use is confined to carefully monitored trials, often in palliative or superficially located tumors where the risk-benefit balance is more favorable. As results accumulate, the field will need randomized comparisons against standard regimens to determine whether the promise of better normal-tissue sparing translates into longer survival, improved function, or both.
For patients and clinicians, FLASH radiotherapy represents a tantalizing possibility: delivering curative doses in less than the blink of an eye while reducing collateral damage. The transition from proof-of-concept cases and animal models to routine clinical practice will likely take years. Not every tumor or treatment site may be suited to this approach. But if ongoing trials confirm the early signals, ultrafast radiation could fundamentally reshape how oncologists think about both the physics and biology of dose delivery, opening a new era in which timing is as critical as total dose in the fight against cancer.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
